Om deze cursus te volgen, moet u een account hebben en ingelogd zijn.

Omschrijving

While our armamentarium of so-called high-efficacy drugs grows, each has distinct impacts on the immune system and the underlying disease processes. Mastering these different modes of actions and their consequences is a key when choosing for the most adapted treatment option for an individual patient, as it is for the estimating future risks and for moving from one DMD to another if and when it's necessary.

 

MS, a complex disease, often requires multidisciplinary interventions. DMDs first act is upon the disease activity, but they can also impact other invisible aspects of the disease such as the Quality of Life (QoL) and societal cost. For this reason, the choice of a DMD goes beyond purely controlling the disease.

Spreker(s)

Steven Simoens

Health economist

KU Leuven

Bassem Yamout

Professor of Neurology

American University of Beirut
President, MENACTRIMS
Director, Neurology Institute and MS centre Harley street MC Abu Dhabi UAE

Misschien bent u ook geïnteresseerd in deze cursussen

Prof. dr. Paul Boon et Prof. dr. Lieven Lagae

Belgian Epilepsy Recommendation

Geaccrediteerd voor artsen 

  • 10 Hoofdstukken
  • 01h

Professor Sarah Weckhuysen et Professor Nicolas Gaspard

AES Highlights

Geaccrediteerd voor artsen (21013728)

  • 14 Hoofdstukken
  • 01h 26min

Childhood Epilepsy Symposium

Geaccrediteerd voor artsen (21013801 - 2CP)

  • 16 Hoofdstukken
  • 01h 46min

Gezondheidseconomische evaluaties toegepast op oncologie

Geaccrediteerd voor artsen - 21007826 - 1CP Ethiek en Economie

  • 6 Hoofdstukken
  • 01h 05min